1-[[[5'-[[1-(4-Chloro-3-methylphenyl)ethyl]amino]-2'-fluoro-3,5-dimethyl[1,1'-biphenyl]-4-yl]carbonyl]amino]-cyclopropanecarboxylic acid
CAS: 1233332-37-0
Ref. 3D-IZB33237
5mg | Discontinued | ||
10mg | Discontinued | ||
25mg | Discontinued | ||
50mg | Discontinued | ||
100mg | Discontinued |
Product Information
- 1-[[[5′-[[1-(4-Chloro-3-methylphenyl)ethyl]amino]-2′-fluoro-3,5-dimethyl[1,1′-biphenyl]-4-yl]carbonyl]amino]cyclopropanecarboxylic acid
- Ex 26
- Cyclopropanecarboxylic acid, 1-[[[5′-[[1-(4-chloro-3-methylphenyl)ethyl]amino]-2′-fluoro-3,5-dimethyl[1,1′-biphenyl]-4-yl]carbonyl]amino]-
1-[[[5'-[[1-(4-Chloro-3-methylphenyl)ethyl]amino]-2'-fluoro-3,5-dimethyl[1,1'-biphenyl]-4-yl]carbonyl]amino]-cyclopropanecarboxylic acid (EMPA) is a cholesterol lowering drug that has been shown to decrease plasma cholesterol levels in animals. EMPA is a selective inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), which controls the rate of cholesterol synthesis in the liver. The large number of studies on EMPA have found that it also has antiplatelet and antithrombotic effects, as well as antiinflammatory and antioxidant properties. EMPA also has been shown to be effective against hepatic steatosis and Alzheimer's disease in animal models.